Monitor for Phase 1 safety and preliminary efficacy data expected in H1 2027, which could serve as a key catalyst for the stock. The involvement of leading oncology investigators adds credibility to the trial. Consider this a high-risk/high-reward opportunity given the early stage of development but first-in-class mechanism.
Price Chart
Executive Summary
BioLineRx has initiated a Phase 1/2a clinical trial for GLIX1, a first-in-class oral small molecule targeting DNA damage response in glioblastoma (GBM) and other cancers. The trial will enroll up to 30 patients with recurrent GBM to assess safety, dosing, and preliminary efficacy, with data expected in the first half of 2027. The study is led by prominent neuro-oncology experts including Dr. Roger Stupp.
Key Facts
- Initiated Phase 1/2a trial of GLIX1 for recurrent/progressive glioblastoma (GBM) and other high-grade gliomas
- GLIX1 is a first-in-class, oral, small molecule TET2 activator targeting DNA damage repair in cancer cells
- Preclinical data shows potent anti-tumor activity in GBM models, excellent blood-brain barrier penetration, and favorable safety profile
- Phase 1 trial will enroll up to 30 patients to determine maximum tolerated dose and recommended dose
- Initial data from Phase 1 expected in first half of 2027
- Study led by world-renowned glioblastoma investigators including Dr. Roger Stupp, Dr. Alexandra Miller, and Dr. Patrick Grogan
- GLIX1 is being developed under collaboration with Hemispherian AS
- Company's lead development asset, with APHEXDA already approved for stem cell mobilization in multiple myeloma
Financial Impact
No immediate financial impact, but significant potential future value creation if clinical development is successful
Risk Factors
- Early-stage clinical trial with inherent risk of safety issues or lack of efficacy
- Small market cap ($10M) makes the stock highly volatile
- Dependence on successful clinical development of pipeline assets
- Potential for dilution as company may need to raise additional capital
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001178913-26-001738 |
| Document: zk2634945.htm | 0001178913-26-001738 |
| Document: 0001178913-26-001738-index-headers.html | 0001178913-26-001738 |
| Document: 0001178913-26-001738-index.html | 0001178913-26-001738 |
| Document: 0001178913-26-001738.txt | 0001178913-26-001738 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 4d ago | 6-K | $2.04 | awaiting T+20 | — | $2.03 (−0.49%) |
Oct 5, 2026 22d ago | EFFECT | $2.32 | awaiting T+20 | — | $2.03 (+12.50%) |
Sep 25, 2026 4w ago | F-1 | $2.43 $2.00 | ▼ −17.70% | ▼ −17.66% | $2.03 (−16.46%) |
Sep 10, 2026 6w ago | 6-K | $2.57 $2.21 | ▼ −13.99% | ▼ −16.12% | $2.03 (−21.00%) |
Aug 31, 2026 8w ago | 424B5 | $2.80 $2.36 | ▲ +15.71% | ▲ +15.34% | $2.03 (+27.50%) |
Aug 31, 2026 8w ago | 6-K | $2.80 $2.36 | ▲ +15.71% | ▲ +15.34% | $2.03 (+27.50%) |
Aug 31, 2026 8w ago | 6-K | $2.80 $2.36 | ▲ +15.71% | ▲ +15.34% | $2.03 (+27.50%) |
Aug 28, 2026 8w ago | 6-K | $2.60 $2.43 | ▲ +6.54% | ▲ +6.80% | $2.03 (+21.92%) |
Aug 28, 2026 8w ago | Press Release | $2.60 $2.43 | ▲ +6.54% | ▲ +6.80% | $2.03 (+21.92%) |
Jul 8, 2026 15w ago | 6-K | $3.01 $2.72 | ▼ −9.73% | ▼ −13.01% | $2.03 (−32.56%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers